Research programme: inflammatory pain therapeutics - Arissa PharmaAlternative Names: AP 2300; AP 2500; AP 2900
Latest Information Update: 06 Jun 2016
At a glance
- Originator Arissa Pharma
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory pain
Most Recent Events
- 06 Jun 2016 Preclinical trials in Inflammatory pain in China (PO) before June 2016